Germany Infection Control Market - Forecasts from 2020 to 2025
Germany infection control market is estimated to be of worth total market value of USD1,805.949 million by the end of 2025. The market is projected to surge in the forecast period with the high health expenditure of the country. Additionally, with the growing geriatric population of the country, the health expenditure is further going to increase, hence, fueling the market demand in the forecast period. The presence of chronic diseases has increased the need for regular visits to hospitals and clinics, propagating the market growth in the forecast period. Furthermore, the presence of effective cancer care in Germany leading to high cancer survival rates is burgeoning the market demand during the next five years. According to the Federal Ministry of Health, substantial growth of corona virus infections has been recorded in Germany. This will further provide an opportunity for the market to thrive in 2020 in order to prevent further spreading of infections from this deadly virus.
Effective cancer care in the country is poised to surge the growth of the infection control market in the forecast period.
The country is accountable for a high number of cancer survivors, especially for breast cancer, cervical, and colorectal cancer. The major reason is attributed to the high screening rates leading to early cancer detection, which is considered crucial for providing effective care to patients in time. Hence, an early diagnosis is the most important factor, contributing to offering effective cancer care. Furthermore, the rise in regular check-ups for effective cancer treatment is proliferating the market growth in the forecast period.
Hospitals and specialized cancer centers in Germany are well-equipped to provide comprehensive care for all cancer patients and their families. Also, these centers use advanced facilities with the latest medical technology and provide the latest in cancer treatment. Hence, this has further surged the high market demand for state-of-the-art infection control products to keep pace with the advanced healthcare system here. Even the standard hospitals in the country make use of the latest technologies or high-tech imaging for detecting tumors at an early stage. The cancer diagnosis is performed utilizing high-resolution MRI or three-dimensional computed tomography (3D CT scan).
Hospital admissions and growing surgical activity are augmenting the market demand in the forecast period.
As per OECD estimates, the rate of hospital admissions and surgical activity is very high. This is further creating a high market demand in the forecast period. The factors affecting the rate of hospital admissions are due to the growing geriatric population (with one of the oldest populations in the Europe with low fertility rate), further driving the market demand in the forecast period.
The country is recorded to have the highest number of coronary revascularization procedures which is accounted to be more than 400 procedures per 100,000 population (source: OECD, 2016 data). As per the European Union, estimates, in 2017, the transluminal coronary angioplasties were found to be most common in Germany and Croatia. In Germany, the transluminal coronary angioplasty was performed at an average rate of 413 per 100,000 inhabitants in the same year.
Segmentation:
Effective cancer care in the country is poised to surge the growth of the infection control market in the forecast period.
The country is accountable for a high number of cancer survivors, especially for breast cancer, cervical, and colorectal cancer. The major reason is attributed to the high screening rates leading to early cancer detection, which is considered crucial for providing effective care to patients in time. Hence, an early diagnosis is the most important factor, contributing to offering effective cancer care. Furthermore, the rise in regular check-ups for effective cancer treatment is proliferating the market growth in the forecast period.
Hospitals and specialized cancer centers in Germany are well-equipped to provide comprehensive care for all cancer patients and their families. Also, these centers use advanced facilities with the latest medical technology and provide the latest in cancer treatment. Hence, this has further surged the high market demand for state-of-the-art infection control products to keep pace with the advanced healthcare system here. Even the standard hospitals in the country make use of the latest technologies or high-tech imaging for detecting tumors at an early stage. The cancer diagnosis is performed utilizing high-resolution MRI or three-dimensional computed tomography (3D CT scan).
Hospital admissions and growing surgical activity are augmenting the market demand in the forecast period.
As per OECD estimates, the rate of hospital admissions and surgical activity is very high. This is further creating a high market demand in the forecast period. The factors affecting the rate of hospital admissions are due to the growing geriatric population (with one of the oldest populations in the Europe with low fertility rate), further driving the market demand in the forecast period.
The country is recorded to have the highest number of coronary revascularization procedures which is accounted to be more than 400 procedures per 100,000 population (source: OECD, 2016 data). As per the European Union, estimates, in 2017, the transluminal coronary angioplasties were found to be most common in Germany and Croatia. In Germany, the transluminal coronary angioplasty was performed at an average rate of 413 per 100,000 inhabitants in the same year.
Segmentation:
- By Product
- Disinfectant
- Sterilization
- Low temperature Sterilization
- Heat Sterilization
- Contract Sterilization
- By End User Industry
- Healthcare
- Food and Beverage
- Chemical
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porters Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis
5. GERMANY INFECTION CONTROL MARKET ANALYSIS, BY PRODUCT
5.1. Introduction
5.2. Disinfectant
5.3. Sterilization
5.3.1. Low Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. GERMANY INFECTION CONTROL MARKET ANALYSIS, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. Medtronic
8.3. STERIS plc
8.4. Cantel Germany GMBH
8.5. Ecolab
8.6. List is not Exhaustive*
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porters Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis
5. GERMANY INFECTION CONTROL MARKET ANALYSIS, BY PRODUCT
5.1. Introduction
5.2. Disinfectant
5.3. Sterilization
5.3.1. Low Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. GERMANY INFECTION CONTROL MARKET ANALYSIS, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. Medtronic
8.3. STERIS plc
8.4. Cantel Germany GMBH
8.5. Ecolab
8.6. List is not Exhaustive*
